Anthem Biosciences Limited specializes in the production of biologically active peptides and specialty organic molecules for the drug, agrochemical, and specialty chemical sectors. It has reported robust financial growth with a revenue increase of 26.3% YoY for H1FY26. The company completed expansions at Unit II, enhancing production by adding significant capacity for custom synthesis and fermentation. They are strategically entering the biosimilars market, leveraging their integrated capabilities. Anthem solidly positions itself within the biotechnology industry by raising capital through its recent IPO and engaging with major pharma companies.